ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions.
about
Gene discovery for the carcinogenic human liver fluke, Opisthorchis viverriniHepatolithiasis and intrahepatic cholangiocarcinoma: A review.Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapiesGenetic profiling of intrahepatic cholangiocarcinomaMicroRNA-26a promotes cholangiocarcinoma growth by activating β-cateninScreening of potential biomarkers for cholangiocarcinoma by integrated analysis of microarray data sets.Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion.Genetic and molecular abnormalities in cholangiocarcinogenesis.Accumulation of neoplastic traits prior to spontaneous in vitro transformation of rat cholangiocytes determines susceptibility to activated ErbB-2/Neu.miR-21 targets 15-PGDH and promotes cholangiocarcinoma growth.Genome-wide expression patterns associated with oncogenesis and sarcomatous transdifferentation of cholangiocarcinoma.Amplification of D22S283 as a favorable prognostic indicator in liver fluke related cholangiocarcinoma.Real-time PCR-based analysis of the human bile microRNAome identifies miR-9 as a potential diagnostic biomarker for biliary tract cancerPrognostic value of DNA alterations on chromosome 17p13.2 for intrahepatic cholangiocarcinoma.Correlation analysis of liver tumor-associated genes with liver regenerationNew insights on cholangiocarcinoma.Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt.Reappraisal of the therapeutic role of celecoxib in cholangiocarcinoma.Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma.Microsomal prostaglandin E synthase-1 inhibits PTEN and promotes experimental cholangiocarcinogenesis and tumor progression.Characterization of a novel rat cholangiocarcinoma cell culture model-CGCCAOmega-3 Polyunsaturated Fatty Acids Upregulate 15-PGDH Expression in Cholangiocarcinoma Cells by Inhibiting miR-26a/b Expression.FAT, E-cadherin, beta catenin, HER 2/neu, Ki67 immuno-expression, and histological grade in intrahepatic cholangiocarcinoma.Immunodetection of cyclooxygenase-2 (COX-2) is restricted to tissue macrophages in normal rat liver and to recruited mononuclear phagocytes in liver injury and cholangiocarcinomaElevated expression of cyclooxygenase-2 is a negative prognostic factor for overall survival in intrahepatic cholangiocarcinoma.Monoclonal antibodies as effective therapeutic agents for solid tumors.Biliary tract cancers: current concepts and controversies.JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression?Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma.The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer.Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment.Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives.Liver carcinogenesis: rodent models of hepatocarcinoma and cholangiocarcinoma.Mechanisms of biliary carcinogenesis and growthRisk factors for intrahepatic cholangiocarcinoma: a case-control study in China.Genome wide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract.Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinomaEGFR and HER2 expression in advanced biliary tract cancer.Neoplasms of the hepatobiliary system: clinical presentation, molecular pathways and diagnostics.Molecular mechanisms of cholangiocarcinoma.
P2860
Q21266569-644AEE55-76DC-461E-BAAD-A852ECC5BE3FQ26771199-0118C2AA-9BD9-43CB-B1EA-99002455A5A4Q27002547-4F8D2087-1176-40C1-838F-39646BFD0CD1Q27005787-B891E059-C3A1-4BB3-A86A-537A0A5C3CF8Q28263940-5FA96669-5DAF-4BFA-91F6-C17035B30B89Q31032714-675C2E0B-C44D-4268-98C9-63B253B0265DQ33529782-F661EA59-DAA9-4F51-93C9-B11C2F347CD9Q33570262-D4CABEBA-0EDF-41DD-B465-DD25412BD68DQ33575284-AC2E211F-C2DA-4558-AFF2-29CFC8C31879Q33758343-AFC265BD-DC9B-4FAD-B10A-C80AE5DCFAEFQ33824237-07CD8748-8AC5-407F-93FB-23174FB27E46Q33867526-4A84DF6D-5F9A-468B-9252-5817450E0AFEQ33999840-ACCAB5EF-B6A4-44AD-8A6A-2C6B40336398Q34224792-48FC041E-D681-4B7E-A5A4-2A0B04BA7267Q34233029-2B01D99F-49B5-458B-B07F-7AB6D878D7E4Q34391135-AD194EE6-5C2B-4014-AF4A-EAE545E567B5Q34414026-D2B1A7F7-166D-480A-B066-AD1C4FC1B303Q34904867-E8F5E6F9-940B-48CD-8B8E-39FE700727CFQ34978321-2E6DA1A8-F140-4B64-918E-82EEAB8E1275Q35028164-E8836E48-243A-42C0-98D9-8B3612025F08Q35085981-5966B0E0-49E1-4311-A088-57A7532B7F54Q35251736-418DB051-0A71-4AD1-9A9C-059018409C47Q35588892-9F28CA17-8972-4CB2-AB6A-806E06947225Q35683401-8C0A0A72-22BA-4C0E-BB0E-C0D43679E4C0Q35837128-8A1C9BA0-D7FC-4A1D-8E57-06B0F7C1A508Q35857856-FBC87860-7E96-4FDE-BE2F-143C024DDF77Q36066076-3B82B528-3FE4-425D-9237-D21C5D3CB573Q36178175-F25D6619-6A7B-42CC-A6B2-75CB2C7A1D41Q36614705-4BFD7A39-ED05-4CE3-A00E-DE7A01C09876Q36683019-45ED87F4-0C0A-4C0D-AF01-6252EF424023Q36900063-EAEE8F14-2C7D-4863-811F-0CC9BA19E6F1Q36962011-0816B4B4-C82A-44B9-9FC1-BEAFF83D6E65Q37028411-9175C266-9357-4EF2-953A-2EF850EF3B57Q37169351-3FF101C9-6EE3-44AB-B67C-CCAEFE363AD5Q37189634-53BCE663-42A0-4F39-84DE-634F565591A6Q37233632-9F662143-96B9-4C29-BF9B-A7A48A47A5DEQ37351498-D6646231-8CE9-4840-8F45-185C6E08E376Q37362858-AE2BDC65-701A-4242-AA0B-A8B75D4A6E3EQ37801938-DC79D3AF-EE75-41D1-98BB-EADAA18CFE6AQ37878879-DCE6433C-8CDF-4A23-9A0C-662B6C3555C3
P2860
ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
ERBB-2 overexpression and cycl ...... carcinoma and risk conditions.
@en
type
label
ERBB-2 overexpression and cycl ...... carcinoma and risk conditions.
@en
prefLabel
ERBB-2 overexpression and cycl ...... carcinoma and risk conditions.
@en
P2093
P356
P1433
P1476
ERBB-2 overexpression and cycl ...... carcinoma and risk conditions.
@en
P2093
Alphonse E Sirica
Byung-Il Yoon
Chawalit Pairojkul
Kanenori Endo
P304
P356
10.1053/JHEP.2002.34435
P407
P577
2002-08-01T00:00:00Z